Skip to content
The Policy VaultThe Policy Vault

Rozlytrek (entrectinib) — Medica

Non-small cell lung cancer (ROS1-positive metastatic)

Initial criteria

  • age ≥ 18 years
  • patient has metastatic disease
  • disease is ROS1-positive
  • mutation detected by an approved test

Approval duration

1 year